[Cosaldon retard in the treatment of optic neuritis and macular degeneration].
D000368:Aged; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D009539:Nicotinic Acids / Q000627:therapeutic use*; D009902:Optic Neuritis / Q000188:drug therapy*; D013805:Theobromine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013806:Theophylline / Q000031:analogs & derivatives*; D014792:Visual Acuity / Q000187:drug effects; D014794:Visual Fields / Q000187:drug effects; D014971:Xanthinol Niacinate / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D004338:Drug Combinations; D009539:Nicotinic Acids; D014971:Xanthinol Niacinate; D013806:Theophylline; D013805:Theobromine
Cosaldon retard w leczeniu zapalenia nerwu wzrokowego i zmian zwyrodnieniowych plamki.